Ozempic, Wegovy, and Rybelsus are semaglutide-containing drugs from Novo Nordisk. Starting in 2024, there have been reports of non-arteritic anterior ischemic optic neuropathy, or NAION, associated with these semaglutide-containing drugs. And there is new medical evidence in 2026 regarding NAION vision loss with Ozempic, Wegovy, and … [Read more...]
Rybelsus Lawsuits for Pancreatitis Death Cases
We are investigating Rybelsus lawsuits, with a focus on cases of hemorrhagic pancreatitis or necrotizing pancreatitis involving death. Those Rybeslus pancreatitis death cases would be filed against the responsible pharmaceutical company, Novo Nordisk. The best Rybelsus lawsuits would be for people who were diagnosed with hemorrhagic pancreatitis … [Read more...]
Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study
Background: Pembrolizumab (anti-PD-1 antibody) plus lenvatinib (multityrosine kinase inhibitor) showed high clinical activity in PEMMELA cohort 1 in patients with pleural mesothelioma pre-treated with platinum-based chemotherapy. This study (cohort 2) aimed to investigate the clinical activity of this combination in patients with pleural … [Read more...]
Depo-Provera Legal Compensation Cases After Meningioma Warning Added to Drug Label in 2025
Question: Can Depo-Provera legal compensation cases still be filed after a meningioma warning was added in December 2025 to the Depo-Provera drug label? Short Answer: Yes, new Depo-Provera lawsuits can be filed if you received a Depo-Provera injection before December 2025, and were diagnosed with meningioma any time after those … [Read more...]
Semaglutide Deep Vein Thrombosis Case Information: 2026 Medical Journal Article
A 2026 medical journal article, which presented some semaglutide deep vein thrombosis case information, is of interest to us because Ozempic, Wegovy, and Rybelsus — three relatively new semaglutide-containing drugs — have been associated with a significantly increased risk of blood clots. We have been investigating Ozempic, Wegovy, and Rybelsus … [Read more...]
Pericardial Mesothelioma: Diagnostic and Therapeutic Management, a Population-Based Study in Italy
Pericardial mesothelioma (PM) is an extremely rare tumour for which only case reports, small case series, and case reviews have been published. This is a large population-based study on PM in Italy using data from the Italian National Mesothelioma Registry (Registro Nazionale Mesoteliomi, ReNaM). Information collected includes detailed clinical … [Read more...]
NAION Lawsuits Involving Ozempic and Mounjaro
As we have reported previously, vision loss due to Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) lawsuits involving Ozempic and Mounjaro are being filed. These NAION lawsuits seek legal compensation for the person suffering from this serious eye side effect injury. Ozempic NAION lawsuits are filed against Novo Nordisk. Mounjaro NAION … [Read more...]
Pleural Mesothelioma Diagnosis for the Pulmonologist: Steps Along the Way
Background/Objectives: Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor with a poor prognosis and complex diagnostic pathways. Pulmonologists often play a central role in its initial recognition and investigation. This narrative review synthesizes the current evidence on [mesothelioma diagnosis], with emphasis on imaging, tissue … [Read more...]
Andexxa Risks Outweigh Its Benefits, Says FDA In December 2025
When AstraZeneca asserted that their recent Andexxa drug recall had to do with “commercial reasons”, we suggested that there was an Andexxa drug safety issue involved, also, in our December 15, 2025, Drug Injury Watch post, "Andexxa Drug Recall December 2025 Due In Part To Safety Issue That Involves Blood Clots". And this December 18, 2025, FDA … [Read more...]
Global burden of lung cancer attributable to occupational asbestos exposure: 1990 to 2021
Background: Asbestos is a well-established occupational carcinogen, with strong evidence linking its exposure to lung cancer. Despite increasing awareness of its health risks, asbestos continues to be used in many countries. We aimed to evaluate the global burden of lung cancer attributable to occupational asbestos exposure and to analyze its … [Read more...]
- 1
- 2
- 3
- …
- 24
- Next Page »